Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avanz Phleum pratense in grass pollen allergic rhinoconjunctivitis
NCT01438827Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Sep 2011
- Primary completion
- Dec 2012
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of ALK Avanz in allergic rhinoconjunctivitis (ARC), sponsored by ALK-Abelló. Started Sep 2011; status: completed.
02
Drugs
ALK Avanz
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01438827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01438827.